$VistaGen Therapeutics(VTGN.US)$Vistagen Announces Positive Results From Phase 2a Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue. Vistagen Therapeutics Inc: Ph15 Was Safe and Well-Tolerated With an Adverse Event Profile Similar to Placebo
$VistaGen Therapeutics(VTGN.US)$Vistagen Receives Notice From European Patent Office Of Intention To Grant Patent For AV-101 To Treat Neuropathic Pain Benzinga· 4 mins ago
VistaGen Therapeutics股票讨论区
26940 shares at usd 4.6 buy
Update
238k shares bought 5.4
Update
Benzinga· 4 mins ago
暂无评论